spacer
home > ict > summer 2020 > the impact of the eu mdr on medical device supply chains
PUBLICATIONS
International Clinical Trials

The Impact of the EU MDR on Medical Device Supply Chains


As part of its aim to strengthen device safety, the new EU Medical Device Regulation 2017/745 (EU MDR) accords greater responsibility to each entity in the supply chain. The duty of ensuring device compliance now extends to every organisation involved in bringing a device to market, as well as the manufacturer itself. Considering that supply chains may be large and complex, especially for companies with a presence in multiple markets,compliance with the new requirements may be a significant challenge. However, the delay of the EU MDR date of application by a full year – the regulation will now take effect on 26 May 2021 – gives businesses the opportunity to properly review the requirements and take the necessary action.

The regulation also widens the net of responsibility to pharmaceutical, biopharmaceutical, and biologic companies. This is because the EU MDR strengthens oversight of device components within drug device combination products. Previously, combination products with a device component ancillary to the drug were regulated under the EU Medicinal Products Directive. Now, under the EU MDR, the device component is subject to the same level of scrutiny as a stand-alone device. Pharma companies must therefore familiarise themselves with the regulation and understand its implications for any of their products that meet the definition of a medical device. If they are not aware of the requirements, they risk losing market access after the deadline for compliance in 2021.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the Author


Chad Reynolds is a Director of Maetrics Solutions Delivery and leads out SD teams in Europe. Prior to coming to Maetrics, he spent eight years managing a global service organisation, and 11 years in leading quality and regulatory compliance roles with leading medical device companies. With Maetrics Chad has successfully led a two-year QMS remediation and integration project and serves as a Solutions Delivery Director for some of its largest clients. He has proven skills in global QMS remediation and integration, EU MDR, EOs, ISO 13485:2016 and MDSAP gap identification and assessment, risk management to ISO 14971:2012, and compliance project implementation. Chad is a certified quality auditor to ISO 9001:2015 and ISO 13485:2016.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Joining forces against SARS-CoV-2

Laupheim, Germany and Milford, MA, USA, October 08, 2020 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement